ArticleDigital journal of ophthalmology : DJO2025
Effective response to intravitreal faricimab in a patient with myopic neovascular membrane resistant to aflibercept.
Article in Digital journal of ophthalmology : DJO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 56-year-old woman with pathological myopia and macular neovascularization in the right eye was treated with 20 intravitreal injections of aflibercept following a treat-and-extend protocol, with no significant clinical improvement. A single intravitreal injection of faricimab was administered, after which the patient showed complete resolution of subretinal fluid and reduced neovascular lesions. Her visual acuity improved from 20/200 to 20/80 in the right eye, and she remained stable for 9 months without further signs of neovascular activity. Faricimab, which targets both VEGF-A and Ang-2, may be an effective alternative in myopic neovascular membranes resistant to aflibercept. Larger studies are needed to explore the long-term efficacy of faricimab in treating pathological myopia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.